Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

Eli Lilly remains the dominant GLP-1 leader, with Q1 2026 revenue of $19.8B, up 56%, and profit nearly tripling to $7.4B as Mounjaro sales rose 125% and Zepbound sales rose 80%. The article argues Lilly's valuation at 39x trailing earnings limits upside, while Viking Therapeutics offers higher-risk/higher-reward exposure as VK2735 advances through phase 3 trials and showed up to 15% average weight loss in earlier studies. Overall tone is constructive on the GLP-1 market but more speculative on Viking as a potential upside play.

Analysis

The key market structure point is that GLP-1 is evolving from a single-category obesity trade into a platform market with multiple dosing forms, tolerability profiles, and prescriber segments. That matters because leadership may not consolidate into one winner; instead, the market can support a premium incumbent plus an earlier-stage challenger if the latter differentiates on access, convenience, or adverse-event profile. The second-order beneficiaries are not just the drug developers but also contract manufacturers, injectables supply chains, and, longer term, oral-formulation enablers that can scale distribution more cheaply than branded injectables.

LLY is a quality compounder, but the market is already paying for near-perfect execution and extended dominance. At this size, incremental upside is less about growth surprises and more about sustaining an unusually high earnings multiple through several expansion cycles; that leaves the stock vulnerable to any disappointment in pricing, reimbursement, or manufacturing cadence. In other words, the risk is not a collapse in fundamentals but multiple compression if investors decide peak enthusiasm has front-run the next leg of growth.

VKTX is the cleaner asymmetric setup because the current valuation implies little probability of success, while late-stage progress creates a binary rerating path over the next 6-18 months. The real optionality is not simply FDA approval; it is the market’s willingness to assign platform value to oral and injectable versions simultaneously, which can push the stock from ‘single-asset biotech’ into ‘strategic acquisition target.’ The main counter-risk is that even good efficacy may be insufficient if tolerability, dose titration, or competitive read-through from larger players weakens differentiation.

Consensus is probably underestimating how much of the GLP-1 opportunity will be captured by companies that solve patient friction rather than maximize headline weight-loss efficacy. That favors VKTX’s right-to-win narrative more than the market’s current discount suggests, while making LLY more of a defensive quality hold than an obvious upside trade. The setup is therefore a classic barbell: expensive leader with lower idiosyncratic risk versus cheap challenger with a much steeper but less certain payoff path.

Key Decisions for Investors

• Go long VKTX as a starter position ahead of key phase 3/late-stage updates; size it as a binary catalyst trade, targeting 2-4x upside on approval/positive differentiation versus a near-total drawdown if data disappoints.
• Use LLY as a relative-value hedge against GLP-1 enthusiasm: short-dated covered calls or a call spread to harvest elevated valuation while retaining exposure to continued execution; this works best over the next 1-3 quarters if sentiment remains crowded.
• Pair trade: long VKTX / short LLY on a 6-12 month horizon. The thesis is not that VKTX is superior operationally today, but that the market is likely overpaying for certainty and underpricing approval optionality.
• If available, express the view via options instead of outright equity: buy VKTX calls into data windows and finance them with downside-defined LLY call overwrites. This preserves convexity around trial milestones while limiting mark-to-market risk.
• Watch for any manufacturing, pricing, or reimbursement headlines on LLY as a signal to trim exposure; those are the most likely triggers for multiple compression, even if revenue growth remains strong.